Projects per year
Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.
- 3 Similar Profiles
Hemophilia A
Medicine & Life Sciences
Factor VIII
Medicine & Life Sciences
Hemorrhage
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Half-Life
Medicine & Life Sciences
Antibodies
Medicine & Life Sciences
Healthy Volunteers
Medicine & Life Sciences
von Willebrand Diseases
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 1993 2023
A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector Mediated Gene Transfer of Human Factor VIII at a dose of 4E13 vg/kg inHemophilia A Patients with Residual FVIII Levels
7/15/18 → 7/15/23
Project: Research project
Transfer Factor
Dependovirus
Hemophilia A
Safety
Genes
United States Health Resources and Services Administration
A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Residual FVIII Levels...
5/1/18 → 7/15/23
Project: Research project
Transfer Factor
Dependovirus
Hemophilia A
Safety
Genes
Factor VIII
Hemophilia A
Hemorrhage
Patient Reported Outcome Measures
ECHO: Expanding Communications on Hemophilia-A Outcomes.
BAYER HEALTHCARE PHARMACEUTICALS
7/1/16 → 12/31/21
Project: Research project
Hemophilia A
Registries
Patient Reported Outcome Measures
Research Output 1997 2019
BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
Lalezari, S., Reding, M. T., Pabinger, I., Holme, P. A., Negrier, C., Chalasani, P., Shin, H. J., Wang, M., Tseneklidou-Stoeter, D. & Maas Enriquez, M., Nov 1 2019, In : Haemophilia. 25, 6, p. 1011-1019 9 p.Research output: Contribution to journal › Article
Open Access
Factor VIII
Hemorrhage
Hemophilia A
Therapeutics
BAY 94-9027
Reversal of acquired von Willebrand syndrome with allogeneic stem cell transplant for chronic lymphocytic leukemia
Hegerova, L., He, F. C., Zantek, N. D., Vercellotti, G. M., Holtan, S. G. & Reding, M. T., Jul 1 2019, In : Blood Cells, Molecules, and Diseases. 77, p. 109-112 4 p.Research output: Contribution to journal › Article
von Willebrand Factor
B-Cell Chronic Lymphocytic Leukemia
Stem Cells
Transplants
Antibodies
Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial
Santagostino, E., Lalezari, S., Reding, M. T., Ducore, J., Ng, H. J., Poulsen, L. H., Michaels, L. A. & Linardi, C. C. G., Nov 2019, In : Thrombosis Research. 183, p. 13-19 7 p.Research output: Contribution to journal › Article
Open Access
Factor VIII
Hemophilia A
Half-Life
Clinical Trials
Safety
1
Citation
(Scopus)
Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation
Hegerova, L., Bachan, A., Cao, Q., Vu, H. X., Rogosheske, J., Reding, M. T., Brunstein, C. G., Arora, M., Ustun, C., Vercellotti, G. M. & Bachanova, V., Dec 1 2018, In : Biology of Blood and Marrow Transplantation. 24, 12, p. e20-e25Research output: Contribution to journal › Article
Stem Cell Transplantation
Lymphoma
Thrombosis
Catheters
Cell Transplantation
2
Citations
(Scopus)
Hematologic Problems in the Surgical Patient: Bleeding and Thrombosis
Jaffer, I. H., Reding, M. T., Key, N. S. & Weitz, J. I., Jan 1 2018, Hematology: Basic Principles and Practice. Elsevier Inc., p. 2304-2312.e4Research output: Chapter in Book/Report/Conference proceeding › Chapter
Thrombosis
Hemorrhage